Cargando…

Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome

BACKGROUND: Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial proportion of patients after the apparent success. No laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasternak, Alexander O., Jurriaans, Suzanne, Bakker, Margreet, Prins, Jan M., Berkhout, Ben, Lukashov, Vladimir V.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795168/
https://www.ncbi.nlm.nih.gov/pubmed/20046870
http://dx.doi.org/10.1371/journal.pone.0008490
_version_ 1782175419124940800
author Pasternak, Alexander O.
Jurriaans, Suzanne
Bakker, Margreet
Prins, Jan M.
Berkhout, Ben
Lukashov, Vladimir V.
author_facet Pasternak, Alexander O.
Jurriaans, Suzanne
Bakker, Margreet
Prins, Jan M.
Berkhout, Ben
Lukashov, Vladimir V.
author_sort Pasternak, Alexander O.
collection PubMed
description BACKGROUND: Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial proportion of patients after the apparent success. No laboratory markers are known that are predictive of cART outcome in initial responders during the period of undetectable plasma viremia. METHODOLOGY/PRINCIPAL FINDINGS: Here, we report the results of a retrospective longitudinal study of twenty-six HIV-infected individuals who initially responded to cART by having plasma viremia suppressed to <50 copies/ml. Eleven of these patients remained virologically suppressed, whereas fifteen experienced subsequent cART failure. Using sensitive methods based on seminested real-time PCR, we measured the levels of HIV-1 proviral (pr) DNA, unspliced (us) RNA, and multiply spliced RNA in the peripheral blood mononuclear cells (PBMC) of these patients at multiple time points during the period of undetectable plasma viremia on cART. Median under-therapy level of usRNA was significantly higher (0.43 log(10) difference, P = 0.0015) in patients who experienced subsequent cART failure than in successfully treated patients. In multivariate analysis, adjusted for baseline CD4(+) counts, prior ART experience, and particular cART regimens, the maximal usRNA level under therapy was the best independent predictor of subsequent therapy failure (adjusted odds ratio [95% CI], 24.4 [1.5–389.5], P = 0.024). The only other factor significantly associated with cART failure was prior ART experience (adjusted odds ratio [95% CI], 12.3 [1.1–138.4], P = 0.042). Levels of usRNA under cART inversely correlated with baseline CD4(+) counts (P = 0.0003), but did not correlate with either baseline usRNA levels or levels of prDNA under therapy. CONCLUSION: Our data demonstrate that the level of HIV-1 usRNA in PBMC, measured in cART-treated patients with undetectable plasma viremia, is a strong predictive marker for the outcome of therapy.
format Text
id pubmed-2795168
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-27951682009-12-31 Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome Pasternak, Alexander O. Jurriaans, Suzanne Bakker, Margreet Prins, Jan M. Berkhout, Ben Lukashov, Vladimir V. PLoS One Research Article BACKGROUND: Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial proportion of patients after the apparent success. No laboratory markers are known that are predictive of cART outcome in initial responders during the period of undetectable plasma viremia. METHODOLOGY/PRINCIPAL FINDINGS: Here, we report the results of a retrospective longitudinal study of twenty-six HIV-infected individuals who initially responded to cART by having plasma viremia suppressed to <50 copies/ml. Eleven of these patients remained virologically suppressed, whereas fifteen experienced subsequent cART failure. Using sensitive methods based on seminested real-time PCR, we measured the levels of HIV-1 proviral (pr) DNA, unspliced (us) RNA, and multiply spliced RNA in the peripheral blood mononuclear cells (PBMC) of these patients at multiple time points during the period of undetectable plasma viremia on cART. Median under-therapy level of usRNA was significantly higher (0.43 log(10) difference, P = 0.0015) in patients who experienced subsequent cART failure than in successfully treated patients. In multivariate analysis, adjusted for baseline CD4(+) counts, prior ART experience, and particular cART regimens, the maximal usRNA level under therapy was the best independent predictor of subsequent therapy failure (adjusted odds ratio [95% CI], 24.4 [1.5–389.5], P = 0.024). The only other factor significantly associated with cART failure was prior ART experience (adjusted odds ratio [95% CI], 12.3 [1.1–138.4], P = 0.042). Levels of usRNA under cART inversely correlated with baseline CD4(+) counts (P = 0.0003), but did not correlate with either baseline usRNA levels or levels of prDNA under therapy. CONCLUSION: Our data demonstrate that the level of HIV-1 usRNA in PBMC, measured in cART-treated patients with undetectable plasma viremia, is a strong predictive marker for the outcome of therapy. Public Library of Science 2009-12-31 /pmc/articles/PMC2795168/ /pubmed/20046870 http://dx.doi.org/10.1371/journal.pone.0008490 Text en Pasternak et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Pasternak, Alexander O.
Jurriaans, Suzanne
Bakker, Margreet
Prins, Jan M.
Berkhout, Ben
Lukashov, Vladimir V.
Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
title Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
title_full Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
title_fullStr Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
title_full_unstemmed Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
title_short Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
title_sort cellular levels of hiv unspliced rna from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795168/
https://www.ncbi.nlm.nih.gov/pubmed/20046870
http://dx.doi.org/10.1371/journal.pone.0008490
work_keys_str_mv AT pasternakalexandero cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome
AT jurriaanssuzanne cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome
AT bakkermargreet cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome
AT prinsjanm cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome
AT berkhoutben cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome
AT lukashovvladimirv cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome